AUTHORS
Tycel Phillips, MD, FASCO, Yan Xu2, Jianyu Wu3, Patricia Marinello, PharmD4, Krish Patel, MD5
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 Merck & Co., Inc., Rahway, New Jersey, United States
3 Merck & Co., Inc., Rahway, New Jersey, United States
4 Merck & Co., Inc., Rahway, New Jersey, United States
5 SCRI Oncology Partners, Nasvhille, Tennessee, United States
ABSTRACT
Background and Significance: Anti-CD20–containing regimens represent the current standard first-line treatment option for patients with advanced follicular lymphoma (FL); however, a substantial proportion of patients experience disease progression or relapse. MK-1045, a humanized bispecific IgG4 CD19 × CD3 T-cell engager, has shown encouraging safety and preliminary efficacy in participants with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (Wang Y et al. Blood. 2025;146[Suppl_1]:647), R/R diffuse large B-cell lymphoma (Song Y et al. Blood. 2025;146[Suppl_1]:3740), and R/R FL (Song Y et al. Blood. 2025;146[Suppl_1]:5372). Here, we describe the ongoing, multicenter, open-label, phase 2/3 WaveSpan-007 study (NCT07634471), designed to evaluate the safety and efficacy of MK-1045 in combination with rituximab versus investigator’s choice of chemotherapy in participants with previously untreated FL.
Study Design and Methods: Eligible participants are adults (aged ≥18 years or >18 years if country-specific requirements apply) with previously untreated, histologically confirmed CD19-positive and CD20-positive classical FL according to the 2022 World Health Organization classification, with Ann Arbor stage II-IV disease and an FL International Prognostic Index score of 2-5. Additional inclusion criteria include radiographically measurable disease per Lugano criteria, clinical features that mandate treatment such as high tumor burden according to Groupe d’Etude des Lymphomes Folliculaires criteria, and an Eastern Cooperative Oncology Group performance status score of 0-2. Key exclusion criteria include having received prior systemic anticancer therapy or radiotherapy, history or presence of clinically relevant central nervous system diseases, history of serious cardiovascular or cerebrovascular disease, and active central nervous system lymphoma or involvement. The study will comprise 2 parts. In part 1 (phase 2), approximately 60 participants with previously untreated FL will receive MK-1045 intravenously once weekly for 12 months plus rituximab (or biosimilar) 375 mg/m2 intravenously every 4 weeks for 6 doses. In part 2 (phase 3), approximately 900 participants will be randomly assigned 1:1 to receive either MK-1045 at the selected dose for 12 months plus rituximab (6 doses) or investigator-selected standard chemoimmunotherapy (bendamustine rituximab [BR]; rituximab, cyclophosphamide, vincristine, and prednisone [R-CVP]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for a total of 6 cycles. The primary end points for part 1 are safety and tolerability, including adverse events (AEs), dose-limiting toxicities, and AEs leading to discontinuation, as well as complete response (CR) per Lugano criteria by investigator review. The dose of MK-1045 for part 2 will be determined based on data from part 1 along with the totality of data generated across the WaveSpan program. The primary end point for part 2 is progression-free survival (PFS) per Lugano criteria by blinded independent central review. Secondary end points include objective response rate (ORR), duration of CR, pharmacokinetics (part 1), CR at 30 months, overall survival (OS), event-free survival (EFS), safety, tolerability, and patient-reported outcomes (part 2). Efficacy will be assessed in all allocated participants who received ≥1 dose of study treatment in part 1 and in the intention-to-treat population, which consists of all randomly assigned participants in part 2. Safety will be assessed in the all participants as treated population in parts 1 and 2. AEs will be graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The point estimate and its 95% CI for CR rate and ORR will be estimated using the exact binomial method proposed by Clopper-Pearson. PFS, OS, and EFS will be estimated using the nonparametric Kaplan-Meier method. Recruitment is currently underway.
DISCLOSURES
Tycel Phillips, MD, FASCO: BMS - Research Funding; Abbvie - Research Funding; Genentech - Research Funding; Sobi - Research Funding; Abbvie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); J&J - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); Immunome - Consultancy (Includes expert testimony); ADCT - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Xencor - Consultancy (Includes expert testimony)